AnaptysBio, Inc. (ANAB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-KT for Q2 FY2026, filed Sep 21, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ANAB SEC filings page.
AnaptysBio, Inc. (ANAB) reported $234.6M in revenue for fiscal year 2025, up 157.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business shifted from heavy development losses to positive cash generation, but shrinking equity makes its balance-sheet leverage more pronounced.
In FY2024, reported operating profit of$66.2M coexisted with operating cash flow of-$135.3M , signaling that accounting profit was not yet cash-backed. By FY2025, operating cash flow turned positive at$19.7M while net income remained a loss of$13.2M , so cash conversion improved without fully closing the operating-to-net earnings gap.
Revenue rose from
Equity fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of AnaptysBio, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
AnaptysBio, Inc. held $211.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $19.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and AnaptysBio, Inc. scores 86/100 among other emerging companies.
AnaptysBio, Inc. had 29M shares outstanding at the end of fiscal year 2025, against 31M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and AnaptysBio, Inc. scores 60/100 among other emerging companies.
AnaptysBio, Inc. spent $136.0M on research and development in fiscal year 2025, which was 1765.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and AnaptysBio, Inc. scores 100/100 among other emerging companies.
AnaptysBio, Inc. reported revenue of $234.6M in fiscal year 2025, against $91.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and AnaptysBio, Inc. scores 94/100 among other emerging companies.
AnaptysBio, Inc.'s operations generated $19.7M of cash in fiscal year 2025, against $135.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and AnaptysBio, Inc. scores 90/100 among other emerging companies.
AnaptysBio, Inc.'s cash, cash equivalents and investments came to $211.6M at the end of fiscal year 2025, against $327.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and AnaptysBio, Inc. scores 48/100 among other emerging companies.
AnaptysBio, Inc. scores 3.26, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.4B) relative to total liabilities ($327.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
AnaptysBio, Inc. passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
AnaptysBio, Inc. reported a net loss of $13.2M while generating $19.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q2 2026.
Cash & Balance Sheet
AnaptysBio, Inc. held $133.8M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
AnaptysBio, Inc. repurchased no shares in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
Not reported for Q2 2026.
ANAB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-KT | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-KT | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $25.6M-8.0% | $108.2M+151.1% | $76.3M+154.3% | $22.3M+102.9% | $27.8M+286.8% | $43.1M+378.8% | $30.0M+804.7% |
| R&D Expenses | N/A | $34.0M-17.5% | $25.6M-40.0% | $31.4M-25.6% | $37.8M-9.9% | $41.2M+11.2% | $42.6M+27.0% | $42.2M+36.7% |
| SG&A Expenses | N/A | $26.2M+85.4% | -$23.6M-27.2% | $10.2M-3.3% | $10.6M+14.1% | $14.1M+14.5% | -$18.6M-280.6% | $10.6M+3.8% |
| Operating Income | N/A | -$34.6M-25.8% | $245.9M+43.4% | $34.7M+252.5% | -$26.2M+35.1% | -$27.5M+34.7% | $171.4M+506.9% | -$22.8M+39.7% |
| EBITDA | N/A | -$34.5M-26.0% | $245.5M+43.6% | $35.1M+255.3% | -$26.3M+34.5% | -$27.4M+34.8% | $171.0M+507.4% | -$22.6M+39.8% |
| Income Tax | N/A | $40K-9.1% | $689K+362.4% | $0 | $39K+333.3% | $44K | $149K | $0 |
| Net Income | N/A | -$52.9M-34.5% | $49.6M+327.8% | $15.1M+146.0% | -$38.6M+17.2% | -$39.3M+10.5% | -$21.8M+48.4% | -$32.9M+11.9% |
| EPS (Basic) | N/A | -$1.84-43.8% | $1.70+357.6% | $0.54+147.4% | -$1.34+21.6% | -$1.28+22.0% | -$0.66+58.5% | -$1.14+19.1% |
| EPS (Diluted) | N/A | -$1.84-43.8% | $1.70+357.6% | $0.52+145.6% | -$1.34+21.6% | -$1.28+22.0% | -$0.66+58.5% | -$1.14+19.1% |
| Diluted Shares (Avg) | N/A | 29M-6.4% | N/A | 29M+0.4% | 29M+5.3% | 31M+14.3% | N/A | 29M+8.8% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
ANAB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-KT | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-KT | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $317.0M-5.4% | $329.7M-21.9% | $364.4M-24.7% | $353.1M-28.4% | $335.3M-21.6% | $422.1M+4.0% | $483.8M+7.0% | $493.4M+1.3% |
| Current Assets | $198.4M-32.0% | $316.1M-12.9% | $350.3M-18.9% | $330.6M-26.3% | $291.9M-20.5% | $363.1M-2.5% | $431.9M+6.2% | $448.7M+4.8% |
| Cash & Equivalents | $133.8M+202.1% | $248.5M+151.9% | $138.2M+498.8% | $109.8M-42.7% | $44.3M-38.3% | $98.6M+83.7% | $23.1M-35.8% | $191.6M+628.6% |
| Short-Term Investments | $30.3M-86.3% | $38.0M-84.3% | $73.4M-72.0% | $139.1M-41.7% | $221.4M-20.6% | $241.3M-19.8% | $262.3M-26.1% | $238.5M-38.3% |
| Long-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $7.7M-72.4% | $28.0M-34.4% | $43.0M+178.0% | $35.5M+31.2% | $27.9M-30.6% |
| Total Liabilities | $306.4M-19.4% | $316.9M-18.3% | $327.2M-20.8% | $382.5M-6.5% | $380.0M-9.0% | $388.0M+8.4% | $413.0M+13.4% | $409.1M+11.5% |
| Current Liabilities | $35.4M-0.5% | $41.7M-5.3% | $38.6M-15.0% | $38.1M-13.2% | $35.5M-12.1% | $44.0M+36.3% | $45.4M+21.3% | $43.9M+12.0% |
| Non-Current Liabilities | $271.0M-21.3% | $275.2M-20.0% | $288.6M-21.5% | $344.4M-5.7% | $344.5M-8.7% | $344.0M+5.6% | $367.5M+12.5% | $365.2M+11.4% |
| Total Equity | $10.6M+123.7% | $12.7M-62.5% | $37.2M-47.5% | -$29.4M-134.9% | -$44.7M-552.8% | $34.0M-28.8% | $70.9M-19.6% | $84.4M-29.9% |
| Retained Earnings | -$641.6M+23.4% | -$825.4M-3.4% | -$772.6M-1.7% | -$822.2M-11.5% | -$837.3M-18.8% | -$798.7M-21.4% | -$759.3M-23.6% | -$737.5M-29.0% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ANAB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-KT | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-KT | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$26.6M+33.8% | -$25.9M-142.2% | $98.0M+247.0% | -$27.4M-171.1% | -$40.2M-88.7% | -$10.7M+71.3% | -$66.7M-94.1% | -$10.1M+72.3% |
| Depreciation & Amortization | -$121K+11.0% | $130K-11.0% | -$408K+7.5% | $418K+190.3% | -$136K-188.3% | $146K-10.4% | -$441K-367.3% | $144K-8.9% |
| Stock-Based Compensation | N/A | $14.2M+55.0% | N/A | $9.2M+11.8% | $9.2M+22.5% | $9.2M-9.5% | N/A | $8.2M+4.9% |
| Capital Expenditures | N/A | $17K-51.4% | $1K-99.6% | $12K-65.7% | $39K+18.2% | $35K+29.6% | $263K-6.1% | $35K-78.4% |
| Free Cash Flow | N/A | -$25.9M-141.6% | $98.0M+246.4% | -$27.4M-170.3% | -$40.3M-88.6% | -$10.7M+71.2% | -$66.9M-93.3% | -$10.1M+72.4% |
| Investing Cash Flow | $7.6M-91.8% | $35.0M+135.6% | $73.5M+178.7% | $47.6M-18.8% | $92.1M+3871.7% | $14.8M-78.4% | -$93.4M-290.0% | $58.6M+91.3% |
| Financing Cash Flow | -$95.6M-89.2% | $1.2M+104.2% | -$43.1M-256.5% | -$10.4M-114.6% | -$50.5M-220.5% | -$28.6M-109.7% | $27.6M+634.3% | $71.2M+2418.7% |
| Share Buybacks | $0-100.0% | $0-100.0% | $3.4M+642.1% | $9.7M | $51.1M | $4.4M | $456K | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
ANAB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-KT | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-KT | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | -135.5% | 61.8%+84.2pp | 45.5%+121.3pp | -117.5% | -99.2% | -22.4% | -75.8% |
| Net Margin | N/A | -206.9% | 45.8%+96.4pp | 19.8% | -173.5% | -141.6% | -50.5% | -109.4% |
| Return on Equity | N/A | -414.9%-299.3pp | 133.3%+164.1pp | N/A | N/A | -115.6%-23.6pp | -30.7%+17.2pp | -38.9%-8.0pp |
| Return on Assets | N/A | -16.0%-6.7pp | 13.6%+18.1pp | 4.3%+10.9pp | -11.5%-0.6pp | -9.3%+1.5pp | -4.5%+4.8pp | -6.7%+1.0pp |
| Current Ratio | 5.61-2.6x | 7.58-0.7x | 9.07-0.4x | 8.68-1.5x | 8.22-0.9x | 8.25-3.3x | 9.51-1.4x | 10.23-0.7x |
| Debt-to-Equity | 28.95 | 24.86+13.5x | 8.79+3.0x | N/A | N/A | 11.41+3.9x | 5.83+1.7x | 4.85+1.8x |
| Asset Turnover | N/A | 0.080.0x | 0.30+0.2x | 0.22+0.2x | 0.070.0x | 0.070.0x | 0.09+0.1x | 0.06+0.1x |
| FCF Margin | N/A | -101.5% | 90.5% | -35.9%-2.1pp | -180.9% | -38.7% | -155.3% | -33.7% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AnaptysBio, Inc. ANAB | FY2025 | $234.6M | -$13.2M | -5.6% | $1.4B | 80/100 |
| Rigel Pharmaceuticals Inc. (New) RIGL | FY2025 | $294.3M | $367.0M | N/A | $861.3M | 62/100 |
| Palvella Therapeutics, Inc. PVLA | FY2025 | N/A | -$41.7M | N/A | $1.8B | — |
| Keros Therapeutics, Inc. KROS | FY2025 | $243.9M | $87.0M | 35.7% | $218.3M | 91/100 |
Where AnaptysBio, Inc. Ranks
Frequently Asked Questions
What is AnaptysBio, Inc.'s annual revenue?
AnaptysBio, Inc. (ANAB) reported $234.6M in total revenue for fiscal year 2025. This represents a 157.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is AnaptysBio, Inc.'s revenue growing?
AnaptysBio, Inc. (ANAB) revenue grew by 157.0% year-over-year, from $91.3M to $234.6M in fiscal year 2025.
Is AnaptysBio, Inc. profitable?
No, AnaptysBio, Inc. (ANAB) reported a net income of -$13.2M in fiscal year 2025, with a net profit margin of -5.6%.
What is AnaptysBio, Inc.'s EBITDA?
AnaptysBio, Inc. (ANAB) had EBITDA of $226.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is AnaptysBio, Inc.'s operating margin?
AnaptysBio, Inc. (ANAB) had an operating margin of 96.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is AnaptysBio, Inc.'s net profit margin?
AnaptysBio, Inc. (ANAB) had a net profit margin of -5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is AnaptysBio, Inc.'s return on equity (ROE)?
AnaptysBio, Inc. (ANAB) has a return on equity of -35.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is AnaptysBio, Inc.'s free cash flow?
AnaptysBio, Inc. (ANAB) generated $19.6M in free cash flow during fiscal year 2025. This represents a 114.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is AnaptysBio, Inc.'s operating cash flow?
AnaptysBio, Inc. (ANAB) generated $19.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are AnaptysBio, Inc.'s total assets?
AnaptysBio, Inc. (ANAB) had $364.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are AnaptysBio, Inc.'s capital expenditures?
AnaptysBio, Inc. (ANAB) invested $87K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does AnaptysBio, Inc. spend on research and development?
AnaptysBio, Inc. (ANAB) invested $136.0M in research and development during fiscal year 2025.
What is AnaptysBio, Inc.'s current ratio?
AnaptysBio, Inc. (ANAB) had a current ratio of 9.07 as of fiscal year 2025, which is generally considered healthy.
What is AnaptysBio, Inc.'s debt-to-equity ratio?
AnaptysBio, Inc. (ANAB) had a debt-to-equity ratio of 8.79 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is AnaptysBio, Inc.'s return on assets (ROA)?
AnaptysBio, Inc. (ANAB) had a return on assets of -3.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is AnaptysBio, Inc.'s P/E ratio?
AnaptysBio, Inc. (ANAB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.4B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AnaptysBio, Inc.'s price-to-sales ratio?
AnaptysBio, Inc. (ANAB) trades at 5.8x sales, its market capitalization divided by revenue of $234.6M revenue, FY2025. The market capitalization is $1.4B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AnaptysBio, Inc.'s Altman Z-Score?
AnaptysBio, Inc. (ANAB) has an Altman Z-Score of 3.26, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is AnaptysBio, Inc.'s Piotroski F-Score?
AnaptysBio, Inc. (ANAB) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are AnaptysBio, Inc.'s earnings high quality?
AnaptysBio, Inc. (ANAB) reported a net loss of $13.2M while generating $19.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is AnaptysBio, Inc.?
AnaptysBio, Inc. (ANAB) scores 80 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.